Literature DB >> 21558091

Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.

El Mustapha Bahassi1.   

Abstract

Polo-like kinases (Plks) are a family of serine-threonine kinases that play a pivotal role in cell cycle progression and in cellular response to DNA damage. The Plks are highly conserved from yeast to mammals. There are five Plk family members (Plk1-5) in humans, of which Plk1, is the best characterized. The Plk1 isoform is being aggressively pursued as a target for cancer therapy, following observations that this protein is overexpressed in human tumors and is actively involved in malignant transformation. The roles of Plks in mitotic entry, spindle pole functions and cytokinesis are well established and have been the subject of several recent reviews. In this review, we discuss functions of Plks other than their classical roles in mitotic progression. When cells incur DNA damage, they activate checkpoint mechanisms that result in cell cycle arrest and allow time for repair. If the damage is extensive and cannot be repaired, cells will undergo cell death by apoptosis. If the damage is repaired, cells can resume cycling, as part of the process known as checkpoint recovery. If the damage is not repaired or incompletely repaired, cells can override the checkpoint and resume cycling with damaged DNA, a process called checkpoint adaptation. The Plks play a role in all three outcomes and their involvement in these processes will be the subject of this review.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558091     DOI: 10.1258/ebm.2011.011011

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  16 in total

Review 1.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

Review 2.  When genome integrity and cell cycle decisions collide: roles of polo kinases in cellular adaptation to DNA damage.

Authors:  Diego Serrano; Damien D'Amours
Journal:  Syst Synth Biol       Date:  2014-07-27

3.  Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.

Authors:  Michel D Wissing; Janet Mendonca; Madeleine S Q Kortenhorst; Nadine S Kaelber; Matthew Gonzalez; Eunice Kim; Hans Hammers; Paul J van Diest; Michael A Carducci; Sushant K Kachhap
Journal:  FASEB J       Date:  2013-07-24       Impact factor: 5.191

4.  Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Authors:  Anita T Tandle; Tamalee Kramp; Whoon J Kil; Aditya Halthore; Kristen Gehlhaus; Uma Shankavaram; Philip J Tofilon; Natasha J Caplen; Kevin Camphausen
Journal:  Eur J Cancer       Date:  2013-06-18       Impact factor: 9.162

5.  Link between DNA damage and centriole disengagement/reduplication in untransformed human cells.

Authors:  Stephen Douthwright; Greenfield Sluder
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

Review 6.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Authors:  Helen M Coley; Eleftheria Hatzimichael; Sarah Blagden; Iain McNeish; Alastair Thompson; Tim Crook; Nelofer Syed
Journal:  Oncotarget       Date:  2012-01

Review 7.  Families of microRNAs Expressed in Clusters Regulate Cell Signaling in Cervical Cancer.

Authors:  Luis Steven Servín-González; Angelica Judith Granados-López; Jesús Adrián López
Journal:  Int J Mol Sci       Date:  2015-06-05       Impact factor: 5.923

8.  Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

Authors:  Ying Shen; Jie Li; Masayuki Nitta; Diahnn Futalan; Tyler Steed; Jeffrey M Treiber; Zack Taich; Deanna Stevens; Jill Wykosky; Hong-Zhuan Chen; Bob S Carter; Oren J Becher; Richard Kennedy; Fumiko Esashi; Jann N Sarkaria; Frank B Furnari; Webster K Cavenee; Arshad Desai; Clark C Chen
Journal:  Oncotarget       Date:  2015-05-20

9.  Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).

Authors:  Liangzhen Jiang; Yan Huang; Min Deng; Ting Liu; Wenbin Lai; Xin Ye
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

Review 10.  Multistep model of cervical cancer: participation of miRNAs and coding genes.

Authors:  Angelica Judith Granados López; Jesús Adrián López
Journal:  Int J Mol Sci       Date:  2014-09-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.